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Abstract
Mycobacterium tuberculosis remains a significant threat to global health. Macrophages are the host cell for M. tuberculosis
infection, and although bacteria are able to replicate intracellularly under certain conditions, it is also clear that
macrophages are capable of killing M. tuberculosis if appropriately activated. The outcome of infection is determined at least
in part by the host-pathogen interaction within the macrophage; however, we lack a complete understanding of which host
pathways are critical for bacterial survival and replication. To add to our understanding of the molecular processes involved
in intracellular infection, we performed a chemical screen using a high-content microscopic assay to identify small
molecules that restrict mycobacterial growth in macrophages by targeting host functions and pathways. The identified
host-targeted inhibitors restrict bacterial growth exclusively in the context of macrophage infection and predominantly fall
into five categories: G-protein coupled receptor modulators, ion channel inhibitors, membrane transport proteins, anti-
inflammatories, and kinase modulators. We found that fluoxetine, a selective serotonin reuptake inhibitor, enhances
secretion of pro-inflammatory cytokine TNF-a and induces autophagy in infected macrophages, and gefitinib, an inhibitor of
the Epidermal Growth Factor Receptor (EGFR), also activates autophagy and restricts growth. We demonstrate that during
infection signaling through EGFR activates a p38 MAPK signaling pathway that prevents macrophages from effectively
responding to infection. Inhibition of this pathway using gefitinib during in vivo infection reduces growth of M. tuberculosis
in the lungs of infected mice. Our results support the concept that screening for inhibitors using intracellular models results
in the identification of tool compounds for probing pathways during in vivo infection and may also result in the
identification of new anti-tuberculosis agents that work by modulating host pathways. Given the existing experience with
some of our identified compounds for other therapeutic indications, further clinically-directed study of these compounds is
merited.
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Introduction
Tuberculosis continues to be a cause of significant morbidity
and mortality world-wide due to numerous factors, including
the rise of drug resistance and the absence of an effective
vaccine. The challenge of adherence to long treatment regimens
and the limited number of effective therapeutics drive the need
for innovative therapeutic strategies that are predicated on a
better understanding of the biology of infection. For example,
the fact that the majority of people infected with the bacillus
never develop active disease suggests that human immunity is
actually quite effective at controlling M. tuberculosis;an o v e l ,
potentially more effective therapeutic strategy could emerge if
we were able to understand and leverage the basis for this
control.
The cellular interaction between M. tuberculosis and macrophag-
es is crucial for determining the outcome of infection. Early in
infection, macrophage microbicidal mechanisms actively work to
try to clear the bacteria; however, macrophage responses that are
adequate to kill other bacterial pathogens often fail to clear M.
tuberculosis. In a majority of individuals, the activation of
macrophages by IFN-c can result in control but not sterilization
of infection, instead driving it into a latent state. During latency,
the macrophage can be a niche where the bacteria are protected
from assaults by the immune system and antibiotic therapy, thus
facilitating their persistence and ultimate dissemination.
PLOS Pathogens | www.plospathogens.org 1 February 2014 | Volume 10 | Issue 2 | e1003946Recent studies have uncovered a number of processes that are
important to tubercular infection. The ability of M. tuberculosis to
arrest the normal progress of phagosome maturation is critical for
its survival in macrophages [1]; however, the molecular mecha-
nisms on both the pathogen and host sides that account for this
arrest are unclear. For example, while calcium signaling in
macrophages appears to be important in this process, the nature of
the calcium signal and the mechanisms by which M. tuberculosis
actively affects calcium signaling are debated [2,3]. In addition to
phagosome maturation arrest, M. tuberculosis may actively suppress
many other macrophage innate immune responses. For example,
virulent strains of M. tuberculosis actively prevent apoptosis
of infected macrophages, thus preventing bacterial killing by
macrophage efferocytosis and avoiding activation of T-cells
through cross-presentation of antigens by dendritic cells [4,5,6].
M. tuberculosis may also actively prevent activation of the
inflammasome and induction of autophagy [7,8]. In addition to
subversion of immune responses, M. tuberculosis manipulates the
host microenvironment in order to acquire nutrients to promote its
own survival. For example, virulent mycobacteria are able to
induce the development of intracellular lipid bodies which fuse
with M. tuberculosis containing phagosomes and provide a critical
source of carbon [9].
Although we have some insight into the pathways that are
important for M. tuberculosis infection of macrophages, our current
understanding of the mechanisms that determine whether the
macrophage controls bacterial infection or succumbs to its
virulence is incomplete. In order to obtain greater insight into
host factors involved in M. tuberculosis infection, unbiased screening
using RNAi or small molecules targeting host proteins have
recently been performed. Two published RNAi screens, one
genome-wide and one focused on kinases and phosphatases,
identified mammalian proteins that are candidate regulators of M.
tuberculosis infection [10,11]. To provide a functional context for
the identified regulators, the authors constructed a signaling
network by integrating the RNAi screening data with data from
transcriptional profiling. Over half of identified genes were found
to be negative regulators of autophagy, affirming the importance
of this pathway for host defense against M. tuberculosis [10]. In
addition to regulators of autophagy, the networks implicated were
enriched for modules that govern metabolism and signal
transduction, with many of these modules centered around the
serine/threonine kinase AKT.
Kinases are central to mammalian signaling pathways. AKT/
PKB is a key modulator of cellular processes such as growth and
proliferation, glucose metabolism, apoptosis, and autophagy. AKT
is specifically activated during Salmonella infection of host cells by
the bacterial effector SopB and promotes bacterial survival by
prevention of phago-lysosome fusion [12]. Treatment of M.
tuberculosis macrophages with the AKT and PKA inhibitor H-89
also results in inhibition of bacterial growth. However, in contrast
to Salmonella infection, the role of AKT is unknown in M.
tuberculosis infection [12]. Importantly, although AKT was
identified in the network that emerged from the genome-wide
RNAi screen of M. tuberculosis infected THP-1 macrophages, the
kinase itself was neither identified in the primary genome-wide
screen nor in a more directed kinase/phosphatase screen con-
ducted by the same group [11].
Of note, in the RNAi screens that have been reported, the
siRNAs used to decrease host factor expression were added only
after M. tuberculosis had already entered and adapted to the
macrophage microenvironment; thus, these screens were not
designed to identify factors that are crucial for the earliest events in
the host-pathogen interaction. Effective silencing of gene expres-
sion using transfection of siRNA is in part dependent on the half-
life of the targeted protein and occurs on the timescale of hours to
days after transfection. In contrast, a chemical biological approach
has some advantages over RNAi with regard to studying early
events. The rapid binding of small molecules to proteins facilitates
probing the early period immediately after phagocytosis. Because
this period is accompanied by the most significant transcriptional
responses on the part of both the bacterium and the macrophage
[13], events during this time frame are likely important deter-
minants of the outcome of infection. Further, in general, unlike
genetic approaches which can target only one isoform or
homologue at a time, small molecules can inhibit multiple, closely
related isoforms of the same target, thus facilitating the identifi-
cation of host activities performed by two or three closely related
targets with redundant function. In addition, unlike RNAi, small
molecules can inhibit enzymatic function without disrupting larger
complexes with subsequent pleiotropic effects, or can inhibit a
specific function of a protein while leaving other functions intact
[14]. Thus small molecule based screens can provide a valuable
complement to existing datasets obtained using siRNA based
knockdown.
Three recently conducted screens were designed to identify
small molecules that disrupt M. tuberculosis replication in macro-
phages. The first screen used a high-content imaging approach to
identify compounds that directly target bacterial processes during
macrophage growth [15]. A subsequent study by the same group
and using the same screening approach identified an inhibitor of
M. tuberculosis cytochrome bc1 [16]. More recently, a group
reported a screen in which microscopy was used to identify host-
targeted inhibitors that prevent replication of Mycobacterium bovis
BCG in macrophages. This study characterized existing neuro-
tropic drugs that diminish replication of M. tuberculosis in infected
macrophages by inducing autophagy or altering endosomal
trafficking, however the targets of these drugs and their modes
Author Summary
Infection with the bacterial pathogen Mycobacterium
tuberculosis causes the disease tuberculosis (TB) that
imposes significant worldwide morbidity and mortality.
Approximately 2 billion people are infected with M.
tuberculosis, and almost 1.5 million people die annually
from TB. With increasing drug resistance and few novel
drug candidates, our inability to effectively treat all
infected individuals necessitates a deeper understanding
of the host-pathogen interface to facilitate new approach-
es to treatment. In addition, the current anti-tuberculosis
regimen requires months of strict compliance to clear
infection; targeting host immune function could play a
strategic role in reducing the duration and complexity of
treatment while effectively treating drug-resistant strains.
Here we use a microscopy-based screen to identify
molecules that target host pathways and inhibit the
growth of M. tuberculosis in macrophages. We identified
several host pathways not previously implicated in
tuberculosis. The identified inhibitors prevent growth
either by blocking host pathways exploited by M.
tuberculosis for virulence, or by activating immune
responses that target intracellular bacteria. Fluoxetine,
used clinically for treating depression, induces autophagy
and enhances production of TNF-a. Similarly, gefitinib,
used clinically for treating cancer, inhibits M. tuberculosis
growth in macrophages. Importantly, gefitinib treatment
reduces bacterial replication in the lungs of M. tuberculosis-
infected mice.
Host-Targeted Small Molecules to Inhibit Mtb
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complementary screen of a library of known bioactive small
molecules to identify inhibitors of M. tuberculosis replication in
macrophages that are biased towards disrupting host functions.
Our goal was to identify small molecules that specifically target
host proteins to gain insight into host functions required for
controlling M. tuberculosis infection. To focus on early events crucial
for the adaptation of the macrophage for bacterial survival but not
on uptake itself, we added molecules to infected macrophages
immediately after phagocytosis. From this screen, we identified
several classes of host-targeted compounds that limit the ability of
M. tuberculosis to proliferate in macrophages, including kinase
inhibitors, G-protein coupled receptor modulators, and ion
channel inhibitors. Our results are complementary to previously
reported screens, expanding our knowledge of host pathways that
are crucial determinants of infection. Based on the bioactive
molecules identified in our screen, we determined that the SSRI
fluoxetine inhibits M. tuberculosis growth in macrophages, induces
enhanced expression of TNF-a, and enhances autophagy. We
additionally demonstrated a new role for the tyrosine kinase
EGFR during M. tuberculosis infection. Importantly, we showed
that the clinically used EGFR inhibitor gefitinib has efficacy for
preventing bacterial replication in both infected macrophages and
mice, suggesting that EGFR is relevant in vivo. The inhibitors we
have identified will be important tools for studying the host-
pathogen interaction and for testing the importance of host
pathways during in vivo infection in animal models.
Results
Development of a high-throughput, high-content
imaging assay to identify compounds that inhibit M.
tuberculosis growth in macrophages
For identification of small molecules that inhibit M. tuberculosis
replication in macrophages, after significant assay testing (see
Methods S1) we designed a microscopy-based assay with simul-
taneous imaging of macrophages and mycobacteria that provides
the sensitivity to detect modest growth inhibition, easily identifies
compounds with significant macrophage toxicity, and can be
largely automated to allow for the rapid testing of thousands
of compounds (for assay design and development details,
see Methods S1). We used this high-content imaging assay to
monitor the growth of GFP-expressing M. tuberculosis in infected
macrophages.
In designing the assay, we sought to establish growth conditions
that would allow for robust and reproducible replication of
M. tuberculosis in macrophages and a readout that would accurately
reflect bacterial number. Macrophages were infected with
M. tuberculosis constitutively expressing GFP (H37Rv-GFP [18]),
and at various time-points after infection, the cells were fixed and
stained with DAPI to allow for enumeration of macrophages by
microscopy. Because intracellular mycobacteria grow in clumps
rather than as discrete, easily quantifiable spots, we utilized the
open-source image analysis software CellProfiler, which can
simultaneously determine and integrate multiple parameters from
our images [19] to determine an optimal visual parameter that
correlates with bacterial number. We found that GFP pixel
intensity integrated across the field and normalized to macrophage
number best represented growth while also accounting for
differences in surviving macrophage number, and most accurately
reflected bacterial census enumerated by plating for colony
forming units (CFU).
Using this parameter, we tested growth of H37Rv-GFP in a
number of cell lines including THP-1 cells, RAW 264.7, and
J774A.1 cells, and found that J774 murine macrophages allowed
for the most consistent and robust growth, with a bacterial
doubling time equivalent to that measured in axenic culture. The
optimal time-point for measuring growth was 3 days post infection,
when intracellular mycobacterial growth was most homogeneous
and little apparent macrophage death was observed.
We next assessed the heterogeneity of mycobacterial growth and
ability of the assay to reproducibly detect growth inhibition across
large numbers of wells in 96-well format. Using a gradient of
concentrations of rifampicin to model varying degrees of growth
inhibition, we demonstrated that the assay was able to distinguish
growth inhibition of 50% inhibition or less (Figure 1A, Figure S1).
With the highest dose of rifampicin we consistently obtained Z9-
factors of 0.4–0.5, which is borderline in robustness for a high-
throughput screen. However, because bacterial growth based on
imaging across the wells did not follow a Gaussian distribution,
standard statistical methods to assess high-throughput assay
quality, such as Z9-factor, that assume a normal distribution for
high-throughput assays may not accurately assess the robustness of
the assay. We therefore used a bootstrap Monte Carlo analysis as
another means to assess the quality of the assay [20,21] and found
that we were able to consistently distinguish 50% inhibition of
growth as established with our positive controls with a predicted
false negative rate of 0.2% and a false positive rate of 0.13%. We
found these rates to be acceptable, allowing us to progress to high-
throughput screening. Ultimately we compared the list of hits
obtained using either composite z-scores or p-values obtained
using the Monte Carlo bootstrap analysis (both metrics included in
Table S1); we found that the list of hits was essentially the same
using both metrics.
Screening a library of bioactive small molecules and
screen hits
We used the assay to screen a library of 1920 small molecules
from the Broad Institute bioactives collection and an additional
159 kinase inhibitors obtained from Nathanael Gray at the Dana
Farber Cancer Institute (Table S1, Figure S2). One advantage of
screening a library of known bioactives is that compound
annotation can provide initial suggestions about mechanisms of
action, thus facilitating the considerable challenge of target
identification from potential host and bacterial targets. Addition-
ally, the bioactives library is enriched for molecules that target
mammalian proteins, thus allowing for elucidation of novel host/
pathogen biology by focusing on macrophage functions.
In a 96 well format, ,3000 macrophages were plated in each
well and infected with M. tuberculosis strain H37Rv-GFP at a
multiplicity of infection (MOI) of 1:1 for 4 hours, after which time
extracellular bacteria were removed by washing. To facilitate
identification of compounds that restrict intracellular M. tuberculosis
growth rather than inhibit uptake, the compound library was
added after phagocytosis. The average final concentration of small
molecules was 5 mM. After three days, cells were washed, fixed,
stained with DAPI, and imaged with a 46 objective lens on an
ImageXpress Micro high-throughput microscope (Molecular
Devices).
We analyzed our data using both a bootstrap Monte Carlo
analysis and composite z-score and were reassured that both
methods identified the same small molecule hits. (The z-score
cutoff was ,21.5; the p-value cutoff was ,0.025.) From the
primary screen we identified a total of 164 unique small molecules
that resulted in statistically significant growth inhibition when
compared to control wells. We discarded compounds with
significant macrophage toxicity (,50% macrophage survival
relative to controls), known antibiotics, and compounds identified
Host-Targeted Small Molecules to Inhibit Mtb
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culture in a parallel screen [18]. After applying these filters, we were
left with 133 unique non-antibiotic compounds (Table S1) that
restrict growth of M. tuberculosis in macrophages. Based on known
annotation, most identified molecules fall into 5 broad categories: G-
protein coupled receptor (GPCR) modulators, ion channel
modulators, membrane transport protein-acting compounds, anti-
inflammatories, and kinase modulators (Figure 1B). Categorizing
compounds based on known annotations raises the caveat that
activityinthis assay may notnecessarily berelated to theirannotated
activity but rather to another ‘‘off-target’’ effect. However, we
compared the relative representation of activity classes from active
molecules with the library that was screened and found a slight over-
representation of GPCR modulators, ion channel modulators, and
membrane transport protein-acting compounds, and similar repre-
sentation among anti-inflammatory compounds and kinase modu-
lators. The specific categories identified and relative proportions of
hits in each category reflect both underlying biology and represen-
tationofthesecategoriesinthescreenedlibrary.Toassessthesuccess
of the screen, we selected and repurchased a group of 22 compounds
with a range of composite z-scores (24t o21.5) for retesting.
Importantly, our retest rate from these compounds was 90%.
Confirmation of screening candidates by select
compound retesting
As the imaging assay is only a proxy for mycobacterial growth,
selected compounds representing each of the major five classes
were retested using the gold-standard for mycobacterial growth,
colony-forming units (CFU). Compounds repurchased from
commercial sources were tested at multiple concentrations to
demonstrate the dose-dependence of growth-inhibition. J774
murine macrophages were infected with M. tuberculosis strain
H37Rv, treated with three concentrations of each compound, and
allowed to grow for three days. Prior to harvesting cells, we
verified microscopically that there was no significant macrophage
toxicity. Cells were then washed with PBS, lysed, and plated for
CFU. Relative to dimethylsulfoxide (DMSO) controls, fluoxetine
(a selective serotonin reuptake inhibitor; membrane transport
protein), farnesyl thiotriazole (FTT) (a protein kinase C activator;
kinase modulator), AKTi1/2 (an inhibitor of PKA/PKB; kinase
modulator), quinidine (a sodium channel inhibitor; ion channel
inhibitor), and ritanserin (an antagonist at the serotonin 2A
receptor; GPCR modulator) all demonstrated significant dose-
dependent activity against intracellular mycobacteria. At the
maximum concentrations used, inhibition ranged from 50% for
FTT to 75% for fluoxetine (Figure 2A). While this is less than would
be expected from a traditional antibiotic with direct bactericidal
activity, it is consistent with the magnitude potentially expected
when host regulators of infection are targeted [10,11]. A subset of
compounds were additionally retested for activity in 5 point dose-
response using our imaging assay (Figures S3, S4, S5, S6, S7, S8);
observed inhibition was similar to that seen using CFU.
Because immortalized cell lines may contain mutations that
alter signaling pathways and gene expression, we next verified that
these same compounds have similar activity in a primary
macrophage model. Primary mouse bone marrow-derived mac-
rophages (BMDM) were infected with H37Rv and treated with the
same panel of bioactive compounds. Because mycobacteria grow
more slowly in BMDM than in cell lines, infection was allowed to
progress for 5 days. After light microscopy was used to confirm the
absence of macrophage death, cells were washed and lysed, and
then released bacteria were plated for CFU. All tested compounds
had significant activity against M. tuberculosis in BMDM (Figure 2B).
To confirm that the bioactive compounds were acting primarily
on the host cells and were not directly toxic to the bacilli at the
concentrations used in the macrophage infection model, com-
pounds were tested for growth inhibitory activity against
M. tuberculosis growing in axenic culture. At concentrations higher
than the highest concentration used against infected macrophages,
none of the inhibitors had significant activity against M. tuberculosis
growing in axenic culture at any point during a 14-day time course
(Figure S9).
Figure 1. High-content imaging assay development and
categorization of screen hits. (A) J774 cells in 96-well dishes were
infected with GFP-expressing H37Rv at an MOI of 1:1. Cells were then
treated with rifampin at the indicated concentrations. Day 3 after
infection, cells were fixed, stained with DAPI, and imaged for both DAPI
and GFP. Images were analyzed using CellProfiler to determine the
mean integrated GFP intensity across each well normalized to
macrophage number. The graph represents one of four independent
experiments with data represented as an average +/2 SEM for each
condition for 84 wells. (B) Of 133 unique hits in the screen, 41 were
agonists or antagonists at G-protein coupled receptors, 16 were
inhibitors or activators of ion channels, 15 were kinase activators or
inhibitors, 5 were membrane transport modulators, 7 were anti-
inflammatory agents, and 46 did not fall into one of the above major
categories.
doi:10.1371/journal.ppat.1003946.g001
Host-Targeted Small Molecules to Inhibit Mtb
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macrophages treated with host-targeted inhibitors
Host targeted inhibitors that restrict the ability of M. tuberculosis
to proliferate in a macrophage could function in various ways,
such as by activating or enhancing a functional immune response
like autophagy, or by inhibiting a signaling pathway activated by
M. tuberculosis as a virulence mechanism. As a recent genome-wide
RNAi screen that sought to identify host factors that regulate the
ability of M. tuberculosis to replicate in macrophages predominantly
identified negative regulators of autophagy [10], we tested whether
our small molecule inhibitors might function by activating
autophagy. LC3 is a ubiquitin-like protein that localizes to
autophagolysosomes and is used as a specific molecular marker
of autophagy. Upon induction of autophagy, LC3-I is converted to
LC3-II by lipidation by a ubiquitin-like system; this conversion can
be used as a readout of autophagy. Using the LC3 conversion
assay, we determined that relative to uninfected macrophages or
infected macrophages treated with DMSO control, both the
EGFR inhibitor gefitinib and the serotonin transport inhibitor
fluoxetine significantly enhanced autophagy (Figure 3A). Although
the degree of LC3 conversion varied from experiment to
experiment, these inhibitors consistently increased the LC3-I to
LC3-II ratio. Other small molecules, including AKTi1/2,
imatinib, quinidine, and ritanserin, did not consistently or
significantly enhance LC3 conversion. These results suggest that
gefitinib and fluoxetine restrict intracellular mycobacterial growth
at least in part by enhancing host autophagy pathways. As the two
molecules are not structurally related and act within distinct
signaling pathways, there may be multiple routes through which
autophagy can be activated to restrict the growth of M. tuberculosis.
Inflammatory responses of macrophages are enhanced
by treatment with fluoxetine
The capacity to mount an inflammatory cytokine response to
infection is critical to the host capacity to control tuberculosis.
Patients with latent tuberculosis treated with TNF-a inhibitors or
Figure 2. Selected screen hits have dose-dependent activity in J774 cells and bone-marrow derived macrophages. Selected hit
compounds were retested at varying doses in (A) J774 murine macrophages and (B) mouse bone marrow-derived macrophages (BMDM). Cells were
infected with M. tuberculosis strain H37Rv at an MOI of 1:1 and treated with each compound at the indicated doses (mM) after a 4 h phagocytosis
period. At day 3 (J774) or day 5 (BMDM) after infection, cells were washed, lysed, and plated for CFU. Each column represents the mean and standard
deviation of four biological replicates. Each experiment was repeated three times and a representative experiment is shown. With the exception of
fluoxetine at 6.25 mM, all p-values were ,0.05 for the comparison of each compound treatment condition with DMSO. p-values were calculated using
the Mann Whitney U test.
doi:10.1371/journal.ppat.1003946.g002
Host-Targeted Small Molecules to Inhibit Mtb
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reactivation disease [22,23]. Similarly, patients with mutations in
the IFN-c receptor are at increased risk of severe mycobacterial
disease [24]. On a cellular level, infection of macrophages with
bacterial pathogens results in the induction of inflammatory
responses that can ultimately lead to control of infection. M.
tuberculosis infection of unactivated macrophages results in an
induction of cytokines including TNF-a and the production of
reactive oxygen and nitrogen species; however, in the absence of
IFN-c activation, the response is insufficient to control replication.
Host targeted inhibitors could limit intracellular proliferation by
upregulating TNF-a, a cytokine which has been shown to inhibit
mycobacterial growth in macrophages through both nitric oxide
dependent and independent mechanisms [25]. To determine
whether treatment of infected macrophages with our inhibitors
results in upregulation of TNF-a, macrophages were infected with
M. tuberculosis and TNF-a levels were measured in the supernatants
24 h after infection. We found that treatment of infected
macrophages with fluoxetine led to a significant increase in the
amount of TNF-a produced (Figure 3B). This result is consistent
with previous reports that serotonergic drugs including fluoxetine
increase the in vivo levels of inflammatory cytokines, including
TNF-a, both in human subjects and in animal models [26]. Thus,
the effects that we observe in cell culture may be generalizable to a
whole organism. Induction of autophagy has been described among
the effects of TNF-a on macrophages [27]. As fluoxetine both
induces TNF-a and autophagy, fluoxetine may induce autophagy
by increasing levels of TNF-a. These results suggest that host-
targeted therapies have the potential to inhibit M. tuberculosis
proliferation by enhancing host protective inflammatory responses,
at least at the level of the individual macrophage. Given the
widespread clinical use and safety profile of serotonergic drugs such
as the SSRIs, further investigation on whether their administration
could impact tuberculosis treatment would be interesting.
Targeting host kinases to inhibit intracellular
mycobacterial growth
Kinases are important signaling molecules that regulate many
aspects of mammalian cell biology including functions important
for cellular response to infection, such as innate immune pathways,
apoptosis, and autophagy. Kinase signaling has previously been
demonstrated to be important for supporting M. tuberculosis
replication in macrophages [11]. We identified 15 compounds
that are annotated as kinase inhibitors in our screen (Table S1).
Several of the targets of these kinase inhibitors have been
previously implicated in the pathogenesis of M. tuberculosis or
related pathogenic mycobacterial species, validating the capacity
of the screen to identify biologically meaningful results [10,12,28].
H-89, an ATP-competitive inhibitor of kinases including both
AKT and PKA, has been shown to inhibit proliferation of M.
tuberculosis in mouse bone marrow derived macrophages [10,12].
Imatinib, an inhibitor of Ableson family kinases (ABL) was also
recently demonstrated to decrease the ability of M. tuberculosis to
replicate in both macrophages and mice [28,29]. However, the
specific role that these kinases play in supporting replication of M.
tuberculosis in host cells is unclear.
Understanding the role that host kinase signaling has upon M.
tuberculosis macrophage growth is important for understanding the
basic biologyofinfection,but might also havesignificant implications
for the development of host-targeted therapeutics. Several of the
kinase inhibitors identified in our screen are compounds currently
used clinically for non-infectious disease related indications, raising
the possibility of repurposing of such drugs for the treatment of
tuberculosis. To confirm the efficacy of kinase inhibitors, we focused
on three kinases for which inhibitors are currently in clinical use or
development for cancer treatment: AKT, ABL and Epidermal
growth factor receptor (EGFR). For each of these kinases we
identified and tested at least two structurally unrelated compounds
annotated as specific inhibitors of the individual enzymes. Although
in practice a target responsible for any given phenotype is not
necessarily the annotated target, the correlation between structurally
unrelated compounds annotated to have the same target increased
our confidence in compound specificity. Treatment of M. tuberculosis-
infected macrophages with inhibitors targeting AKT (AKTi1/2, H-
89), Abl (imatinib, GNF2), or EGFR (gefitinib, lapatinib) lead to a
.2 fold decrease in bacterial load at the highest tested concentration
of each inhibitor in both J774 macrophages (Figure 4A) and mouse
bone marrow macrophages (Figure 4B).
AKT/PKB and M. tuberculosis infection of macrophages
The serine/threonine kinase AKT/PKB has been previously
implicated in the ability of M. tuberculosis and other bacterial
pathogens to replicate in host cells [10,12]. Treatment of infected
cells with the AKT1 inhibitor H-89 was shown to limit proliferation
of M. tuberculosis in infected mouse macrophages [12] and knocking
Figure 3. Specific compounds enhance autophagy or inflam-
matory cytokine release. (A) J774 murine macrophages were
infected with H37Rv, then treated with the indicated compounds. Cells
were harvested for Western-blot analysis of LC3 conversion from LC3-I
to LC3-II as an indicator of autophagy. Data represents one of three
independent experiments. Densitometry for LC3-II to LC3-I ratio for the
shown Western blot was performed using ImageJ image analysis
software. (B) Cells were infected with H37Rv, then treated with
compound after a 4 hour phagocytosis. Supernatants were collected
at 24 hours after infection and TNF-a concentration was determined by
ELISA. Points represent average for 2 wells +/2 standard deviation. Data
represents one of two independent experiments.
doi:10.1371/journal.ppat.1003946.g003
Host-Targeted Small Molecules to Inhibit Mtb
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creased replication of intracellular M. tuberculosis [10]. In our screen,
in addition to previously identified ATP competitive inhibitor H-89,
which preferentially targets PKAin addition to AKT, we found that
a more specific allosteric inhibitor of AKT, AKTi1/2 [30,31] also
restricts intracellular M. tuberculosis replication. To confirm that
AKT plays a role in M. tuberculosis infection of macrophages, we first
tested to see whether AKT was activated by infection with virulent
M. tuberculosis. AKT activation requires phosphorylation at two
residues, Thr-308 and Ser-473 [32]; Western blot analysis for this
phosphorylation is a standard assay for activation. Using Western
blot analysis for phosphorylation of Ser-473, we observed rapid
activation of AKT upon infection of J774 macrophages with M.
tuberculosis (Figure 5A). Importantly, the activation of AKT was
completely abrogated by treatment with the allosteric inhibitor
AKTi1/2 that is known to block the phosphorylation and activation
of AKT1 and AKT2 (Figure 5B). To genetically confirm the role of
various AKT isoforms in macrophage infection, we knocked down
the expression of AKT1, AKT2, and AKT3 in J774 macrophages
(Figure S10). Similar to previously reported results [10], we found
that the maximum effect was observed with simultaneous knock-
down of AKT1 and AKT2. We also found that knocking down
AKT3 provided little additional benefit (Figure 5C). That silencing
both AKT1 and AKT2 is required for maximal effect may account
for the failure to identify AKT in the original RNAi screens that
target only one isoform at a time, while a small molecule inhibitor
inhibits both isoforms simultaneously.
The role of ABL tyrosine kinase during infection with M.
tuberculosis
Imatinib mesylate (Gleevec, STI-571) is a tyrosine kinase
inhibitor that is currently used therapeutically for treating chronic
Figure 4. Inhibitors of protein kinases impair mycobacterial growth in macrophages. (A) J774 cells or (B) BMDM were infected with M.
tuberculosis strain H37Rv at an MOI of 1:1, and treated with each kinase inhibitor at the indicated concentrations (mM) after a 4 h phagocytosis period.
At day 3 (J774) or day 5 (BMDM) after infection, cells were washed, lysed, and plated for CFU. Each column represents the mean and standard
deviation of four biological replicates and each graph represents one of three independent experiments. For (A) all p,0.001 with the exception of
GNF-2 at 2.5 mM, imatinib at 5 mM and gefitinib at 5 mM. For (B) inhibitors were used at the following concentrations: AKTi1/2 5 mM( p ,0.03), H-89
5 mM( p ,0.03), GNF-2 10 uM (not significant), imatinib 5 mM( p ,0.03), gefitinib 5 mM( p ,0.03), lapatinib 5 mM( p = ,0.06). All p values were
calculated using the Mann Whitney U test.
doi:10.1371/journal.ppat.1003946.g004
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tyrosine kinases ABL1 and ABL2 and other related tyrosine
kinases [33]. In fact, imatinib’s activity against CML may require
activity at more than one target [34]. Recently, imatinib was
shown to diminish entry of Mycobacterium marinum in mouse
fibroblasts and M. tuberculosis in mouse macrophages [28]. In
addition, imatinib treatment decreased bacterial replication in
M. marinum and M. tuberculosis infections of mice [28]. Identification
of the ABL inhibitors GNF-2 and imatinib in our screen, which
was designed to avoid inhibition of initial phagocytosis, supports
the idea that ABL is important not simply for cell entry but also for
later replication and survival of mycobacteria in macrophages. A
subsequent study has shown that imatinib increases acidification of
the lysosomal compartment of macrophages. This effect was
required for the anti-mycobacterial activity of the compound [29].
As imatinib inhibits both ABL1 and ABL2, in addition to other
tyrosine kinases, the relevant target during M. tuberculosis infection
of macrophages is not clear. Further, in apparent contradiction,
silencing of abl1 using siRNA has been reported to increase
M. tuberculosis replication in macrophages [11] suggesting that this
family of kinases may play complicated roles during infection. We
therefore sought to characterize the role of ABL1 in entry and
survival of M. tuberculosis in macrophages. To specifically abrogate
ABL1 function, we transfected macrophages with siRNA targeting
abl1. Although we observed significant silencing of ABL1 ex-
pression (Figure S10), we observed no difference in M. tuberculosis
entry into cells treated with abl1-specific siRNA, demonstrating
that ABL1 may not in fact play a role in M. tuberculosis entry
(Figure 5D, Figure S10B). However, after three days of infection
we observed a ,1.9 fold decrease in bacterial replication in cells
treated with siRNA targeting abl1 compared to cells treated with a
non-specific siRNA control, indicating that ABL1 likely plays a
role in M. tuberculosis intracellular survival post entry into
macrophages (Figure 5D). Importantly, knocking down expression
of only ABL1 gave approximately the same magnitude effect
observed in imatinib treated cells (,2.1 fold), suggesting that the
effects of imatinib are likely mediated primarily through ABL1
during M. tuberculosis infection of macrophages.
Figure 5. AKT and ABL are important for mycobacterial infection of macrophages. (A) J774 cells were infected with H37Rv at an MOI of 1
or an MOI of 10. Cells were harvested two hours after infection, and lysates were probed for AKT activation using an antibody to phospho-serine at
position 473. (B) J774 cells were infected with H37Rv at an MOI of 1 for 4 hours, then washed and treated with compound. Cells were harvested at
3 hours after treatment and lysates were probed for AKT activation using an antibody to phospho-serine at position 473. (C) akt1 and akt2 or akt1,
akt2, and akt3 were silenced with siRNA in J774 cells. Cells were then infected with H37Rv at an MOI and 1, and infection was allowed to progress for
3 days. Cells were then lysed and plated for CFU. (D) abl1 was silenced in J774 macrophages using siRNA. Cells were then infected with H37Rv. After
4 hours of phagocytosis, wells were lysed and plated for CFU to determine uptake (day 0). Infection was allowed to progress in the remaining wells;
day 3 after infection, cells were lysed and plated for CFU. Each experiment was repeated a minimum of three times, and a representative experiment
is shown. Error bars are standard deviation, *p=0.0195 by Mann Whitney U for (C) and (D).
doi:10.1371/journal.ppat.1003946.g005
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infection with M. tuberculosis
Although primarily studied in the context of cancer, EGFR has
been linked to influenza uptake [35], to regulation of inflammation
following rhinovirus infection [36], and to prevention of apoptosis
in host cells in bacterially infected gastric epithelial cells [37].
EGFR has not previously been linked to mycobacterial infection.
We identified gefitinib (Iressa, ZD-1839), an EGFR inhibitor used
for treating non-small cell lung cancer [38], and two other EGFR
inhibitors in our primary screen (Table S1). Subsequent testing in
J774 macrophages and BMDM confirmed that gefitinib treatment
controls M. tuberculosis intracellular growth (Figures 4A–4B); we
confirmed that EGFR is in fact expressed in macrophages using
reverse transcription and PCR-based detection of transcript
(Figure S11).
To confirm that the small molecules function by specifically
inhibiting EGFR signaling, we sought to perturb EGFR signaling
in an alternative manner. As EGFR is a well-validated target for
anticancer therapy, several monoclonal antibodies for blocking
human EGFR have been developed. In particular, treatment of
cells with combinations of non-competitive antibodies against
EGFR results in synergistic receptor downregulation via recycling
inhibition in a manner that does not result in activation of EGFR
signaling [39]. We first confirmed that gefitinib effectively blocks
M. tuberculosis replication in primary human monocyte derived
macrophages using a total of four donors (data not shown). Next,
we treated infected human macrophages with two EGFR-
neutralizing antibodies [39]. Treatment with neutralizing anti-
bodies inhibited intracellular M. tuberculosis growth to the same
degree as treatment with gefitinib. (Figure 6A), confirming the role
of EGFR in M. tuberculosis intracellular survival and replication in
primary human macrophages.
Gefitinib inhibits phosphorylation of the downstream
signaling molecule p38 after infection
There are several signaling pathways that can be triggered
downstream of EGFR activation, including activation of AKT,
ERK, JNK, and MAPK p38. To determine whether the effect of
EGFR inhibition was mediated by any of these signaling
pathways, we first sought to determine whether they were
activated by M. tuberculosis infection of macrophages. Both AKT
and p38 were phosphorylated upon infection (Figures 5A and 6B),
consistent with activation. ERK and JNK did not appear to have
increased phosphorylation upon infection (data not shown).
Surprisingly, AKT phosphorylation was not inhibited by gefitinib
treatment (Figure 5B), suggesting that the effect of inhibiting
EGFR during M. tuberculosis infection is independent of AKT
signaling. To determine whether p38 signaling is impacted by
gefitinib, we measured phosphorylation of p38 and found that it
was consistently inhibited in the presence of gefitinib treatment
(Figure 6B). While p38 phosphorylation decreased over time after
infection even in the absence of compound, gefitinib-treated cells
had significantly less p38 phosphorylation than DMSO-treated
cells at multiple timepoints. To determine whether inhibition of
p38 phosphorylation could be the mechanism by which EGFR
inhibition of gefitinib treatment restricts M. tuberculosis growth in
macrophages, we tested whether selective p38a inhibitor AMG548
[40] would also restrict intracellular mycobacterial growth. We
found that inhibition of p38a by AMG548 does in fact restrict
mycobacterial growth in a dose-dependent fashion (Figure 6C).
MAPK p38 has been demonstrated to regulate autophagy via
p38IP and mATG9, with signaling through p38 associated with
inhibition of autophagy and depletion of p38 with activation of
autophagy [41]. Consistent with our finding that gefitinib
induces autophagy (Figure 3A), this report that p38 inhibition
can induce autophagy [41], and our implication of p38 down-
stream of EGFR activation after M. tuberculosis macrophage
infection, we suggest that inhibition of p38 activity downstream
of gefitinib-mediated EGFR inhibition may trigger an increase in
autophagy within the cell, resulting in enhanced clearance of
M. tuberculosis.
Gefitinib is effective for treating M. tuberculosis in vivo
As there are few studies implicating EGFR in bacterial
pathogenesis, we sought to determine whether EGFR signaling
is relevant to M. tuberculosis replication in vivo. Given the problem of
drug-resistant tuberculosis and the long courses of therapy
currently required for treatment, there is growing interest in
host-directed therapies as adjunctive therapy, with the potential to
shorten therapy and increase the efficacy of current antitubercular
antibiotics [11,17,28,42]. To determine whether gefitinib has
efficacy against M. tuberculosis in vivo, we examined the efficacy of
this inhibitor during early acute infection with M. tuberculosis in
the mouse model. We chose to test during early infection prior
to the recruitment of IFN-c producing T cells to the lungs, as this
is the time period that is best modeled by in vitro infection of
unactivated macrophages. BALB/c mice were infected with M.
tuberculosis via aerosol inoculation. Infection was allowed to
progress for 7 days prior to initiation of treatment. Mice were
subsequently treated with gefitinib at a dose of 100 mg/kg every
day for six days. On day 14 after infection, 7 days after initiation of
gefitinib treatment, mice were sacrificed, and lungs were
homogenized and plated for CFU. The experiment was performed
three times and the combined results are shown. Relative to
DMSO-treated control mice, mice treated with gefitinib had
statistically significantly less bacterial burden (Figure 6D). These
results support the in vivo relevance of EGFR in infection and the
idea that host-targeted therapies, and kinase inhibitors specifically,
may be useful as adjunctive treatment for tuberculosis. Further
work will clearly be required to demonstrate efficacy in additional,
more chronic models of M. tuberculosis as well as to determine any
potential benefit when used in combination with traditional anti-
tuberculosis chemotherapeutic agents.
Discussion
We have developed a high-content, high-throughput imaging
assay to identify small molecules that inhibit the growth of
M. tuberculosis within macrophages. We applied our assay to screen
a library of known bioactive molecules, and from that screen
identified several compound classes with diverse annotated
targets that result in reproducible, dose-dependent intracellular
M. tuberculosis growth restriction. Out of the compounds of interest
in our five primary categories, several hits validated previously
described targets [12,28], while others pointed to the involvement
of potentially novel factors important for infection, including
EGFR, the serotonin transporter targeted by SSRIs, serotonin and
dopamine receptors, and sodium channels. An important caveat is
that an annotated mechanism of action may not be relevant to the
actual activity of a compound in a given assay; observed activity
may be due to some other ‘‘off-target’’ effect. Thus, we have used
complementary genetic approaches to validate a few exemplary
small molecules and implicate their annotated targets in our
identified phenotype of M. tuberculosis growth restriction within
macrophages.
Three previous chemical screens had identified compounds that
restrict M. tuberculosis growth within the context of macrophages.
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that are predominantly without known activities [15]. Moreover,
the compounds selected for follow-up target essential bacterial
processes rather than host proteins relevant to the host-pathogen
interaction. A similar screen by the same group also focused on
compounds without known activities that targeted essential
bacterial processes [16]. A third chemical screen was, like our
screen, skewed toward bioactive compounds that target host
proteins [17]. Of our 133 identified active compounds, 21 were
screened by Sundamarthy et al., and of those compounds 13 were
identified as active by their criteria. While distinct libraries
screened explain some of the differences between the lists of hits,
more subtle differences contribute as well. Of the 8 compounds
identified in our screen that were screened but not identified as hits
in the screen by Sundamarthy et al., several score close to their
threshold for consideration as a positive result. The discrepancies
for those compounds likely reflect differences in the precise cutoff
for determining hits and the sensitivity of the respective assays.
However, some clear hits from our screen scored poorly in their
assay, possibly reflecting biological differences between the assays.
While our assay used M. tuberculosis and was designed to identify a
visual output that approximated differences in mycobacterial
growth as optimized using typical antimycobacterial agents, the
assay used by Sundamarthy et al. used Bacille Calmette Guerin
and had a complex visual output based on phenotypic changes
including host cell morphologic changes, phenotypes felt to
represent toxicity to the host cell, bacterial size, bacterial number,
and bacterial intensity. In fact, they report that traditional
antimycobacterial agents did not perform well in their screen,
suggesting that it was not designed primarily to identify molecules
that affect bacterial load when compared to the gold standard of
CFU. Their phenotype likely represented growth restriction
mediated by the particular host processes captured by their visual
output, such as enhanced autophagy, rather than overall growth
restriction. Overlapping hits between the screens may all have a
similar mechanism of growth restriction, while compounds that
Figure 6. EGFR is important for mycobacterial infection of macrophages and in a mouse model of infection. (A) human primary PBMC
derived macrophages were infected with a luciferase-expressing Erdman strain, then treated with EGFR-neutralizing antibodies (aEGFR) and/or
gefitinib at 10 mM (gef) 4 h after the phagocytosis period. Antibodies and inhibitor was refreshed daily, and bacterial growth was determined by
luminescence on day 5 after infection. The data is representative of two independent experiments. (B) J774 cells were infected with M. tuberculosis
strain H37Rv. 4 hours after infection, cells were washed and gefitinib or DMSO was added. Cells were lysed at 15 minutes, 30 minutes, or 60 minutes
after drug treatment and lysates were probed for phospho-p38 and total p38 by Western blot. The data is representative of three independent
experiments. (C) J774 cells were infected with H37Rv-GFP. 4 hours after infection, cells were washed and DMSO or AMG548 was added at the
indicated concentrations. Day 3 after infection, cells were washed and fixed with 4% paraformaldehyde. Plates were imaged and analyzed using our
CellProfiler pipeline to determine integrated GFP intensity normalized to macrophage number. The data represent one of two independent
experiments. (D) Mice were infected with M. tuberculosis strain Erdman via the aerosol route with ,200 CFU and infection was allowed to progress
for 7 days. Beginning day 8 after infection, mice were treated with DMSO or gefitinib 100 mg/kg by intraperitoneal injection daily for six days. Day 14
after infection, mice were sacrificed and lungs were plated for CFU. Data combined from three independent experiments is shown. ***p,0.001,
*p=0.034 by non-parametric Mann-Whitney U test. Error bars are standard deviation.
doi:10.1371/journal.ppat.1003946.g006
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may have distinct mechanisms of action.
We identified several ion channel inhibitors in our screen,
including niguldipine and verapamil, which block calcium
channels, and flecainide and quinidine, which block sodium
channels. A role for voltage-gated calcium channels in mycobac-
terial infection has previously been suggested [43]. In addition to
altering calcium signaling, at least one calcium channel blocker,
verapamil, has been shown to inhibit a bacterial efflux pump that
is important in the context of intracellular infection [44]. Multiple
calcium channel blockers, including verapamil, are used exten-
sively in the clinic for cardiac applications. Our work adds to the
growing body of work that suggests a role for calcium channel
blockers as adjunctive therapy. In fact, in a recent paper, Gupta
et al. tested the addition of verapamil to the standard background
regimen of isoniazid, rifampin, and pyrazinamide to treat
tuberculosis in a murine model, and found that addition of
verapamil both reduced CFU during the active phase of infection
and reduced rates of relapse [45]. Whether these reductions are
the result of the effect of verapamil on the host or the bacterium is
unclear. Nevertheless, this work validates the possibility that
compounds identified in this screen may ultimately be useful as
adjunctive agents for the treatment of tuberculosis. A potential role
for sodium channels has not previously been described and merits
further investigation.
Our second class of targets, GPCRs, has only recently been
suggested to have a role in mycobacterial infection. While recent
work implicated a single GPCR, the D-3-hydroxybutyrate
receptor GPR109A [46], our work identified primarily inhibitors
of central nervous system-associated GPCRs, such as serotonin
receptors and dopamine receptors. Although their function in
macrophages is not well-understood, several central-nervous
system associated GPCRs have been described to be expressed
in macrophages [47,48,49]. While some of these receptors have
previously been shown to have a role in modulating inflammatory
cytokines in response to specific stimulation [50,51], none have
explicitly been shown to be involved in infection or the host-
pathogen interface. Our results raise the intriguing possibility that
these receptors play roles in the host immune response that are
quite distinct from their roles in the central nervous system.
The membrane transport proteins identified in this screen,
including the serotonin transporter targeted by SSRIs, a dopamine
transporter, and an acetylcholine transporter, have similarly not
been shown to be involved in infection previously. Fluoxetine has
been noted to increase systemic TNF-a [26], consistent with our
results. The role of TNF-a during infection with M. tuberculosis is
complex. Low TNF-a levels are clearly detrimental for the host
and lead to impaired control of bacterial replication. However,
overproduction of TNF-a can have host detrimental effects
resulting from excessive tissue damage, induction of macrophage
necrosis, and potentially from signaling bacteria to enter a
nonreplicating antibiotic tolerant state [52,53,54]. Whether the
levels of TNF-a produced during infection of humans with
M. tuberculosis are optimal for bacterial replication or for host
protection is not clear, and this likely varies with the genotype of
both the infecting strain and the infected individual. Tobin et al.
demonstrated in a zebrafish model of M. marinum infection that
particular host genotypes of LTA4H resulted in either high or low
levels of TNF-a production in response to infection, either of
which was detrimental for outcomes. They went on to demon-
strate that promoter polymorphisms for LTA4H in humans
similarly resulted in high or low levels of TNF-a production. In an
elegant translational component of their study, they demonstrated
that among patients with tuberculosis meningitis, only those with
the high- TNF-a producing genotype benefited from the standard
addition of corticosteroids to their therapeutic regimen [52].
Conversely, it is likely that individuals that produce low levels of
TNF-a upon infection with M. tuberculosis may benefit from
adjunctive therapy that enhances production. Given the safety
profiles of SSRIs, their widespread use, and their ability to
modulate TNF-a levels and induce autophagy during infection,
they are attractive candidates for further exploring the possibility
of tailoring TNF-a levels to optimize host response in the infected
individual.
The bulk of the compounds in our anti-inflammatory category
were non-steroidal anti-inflammatories (NSAIDs). Their identifi-
cation is somewhat surprising as their inhibition of cyclooxygenase
should block the production of a metabolite, prostaglandin E2,
previously shown to be protective for infected macrophages and to
reduce the bacterial burden in infected cells [5]. In fact, one would
expect an increase in metabolites generated by competing
pathways, including lipoxygenase-mediated production of lipoxins
such as lipoxin A4, which has been shown to impair the host
response to infection [5]. Thus, an NSAID-induced shift in
metabolic balance away from prostaglandin E2 toward lipoxins
might be expected to worsen the outcome of infection. In contrast,
the identification in our screen of multiple distinct NSAIDs that
restrict M. tuberculosis growth in macrophages suggests that the role
of eicosanoid pathways in mycobacterial infection is potentially
more complex than we understand thus far. Given how
inexpensive, well-studied, and generally well-tolerated NSAIDs
are, they certainly merit further study in animal models of
infection. Corticosteroids were also represented in our anti-
inflammatory category. Anti-inflammatory corticosteroids have
been used as adjunctive therapy for tuberculosis for decades [55].
The use of corticosteroids for tuberculosis meningitis has been
accepted into clinical practice; however, the potential benefit of
adjunctive steroids for any other form of tuberculosis has been a
matter of debate within the literature. A recent meta-analysis
found that steroids significantly reduced mortality associated with
tuberculosis infection of all organ groups [56]. Our finding that
corticosteroids reduce bacterial burden in a cellular model of
infection raises the question of whether steroids might impact
infection at the level of infected macrophages that counteract the
immunosuppressive effects on the whole organism level.
We identified multiple kinase inhibitors in our screen. The
identification of AKT and ABL family inhibitors validated our
screen, as inhibitors of both classes have been previously shown to
disrupt mycobacterial proliferation in macrophages. While a
previous siRNA screen had identified AKT indirectly through
association with genes identified in their screen [10], AKT was not
directly identified using siRNA. Our study demonstrates the
inherent advantage of small molecules over RNAi in simulta-
neously targeting multiple redundant isoforms of a given protein.
Imatinib, an inhibitor of ABL family kinases, had similarly been
demonstrated to be important for mycobacterial infection of
macrophages, predominantly by both inhibiting bacterial uptake
and subsequent replication [28]. Using primarily a model with
M. marinum, which has significant differences from M. tuberculosis in
its intracellular lifestyle, Napier et al. found that the effects of
imatinib were to restrict M. marinum uptake and limit its
intracellular growth, thus implicating imatinib-sensitive tyrosine
kinases as important for virulence. In contrast, a previous study
targeting ABL1 with siRNA suggested that depletion of ABL1
results in increased proliferation of M. tuberculosis in macrophages
[11]. Here we demonstrate that ABL1 is specifically required for
proliferation of M. tuberculosis in macrophages. Our study does not
show reduced uptake of M. tuberculosis in cells treated with imatinib
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expression or inhibition of ABL function seems to specifically
restrict intracellular growth at a later stage.
Finally, we identified EGFR/p38 MAPK signaling pathway as a
novel regulatory pathway during mycobacterial infection that
functions to suppress effective antimicrobial responses. Inhibition
of EGFR appears to restrict growth of intracellular mycobacteria
through induction of autophagy in an AKT-independent mecha-
nism, potentially through downstream inhibition of p38 MAPK.
Previous studies have demonstrated a role for p38 MAPK as a
negative regulator of both basal and starvation-induced autophagy
via p38IP and mATG9 [41]. Our data suggests that EGFRsignaling
during M. tuberculosis infection activates a similar p38 dependent
pathway that prevents clearance of the bacteria byautophagy. Using
an EGFR inhibitor in a murine model of infection, we show the
relevance of EGFR signaling in vivo and demonstrate that targeting
thehostwithcompoundsalreadyinclinicaluseforotherapplications
holdspotentialfornoveltherapeuticsfortuberculosis.Thisworkthus
demonstrates a possible therapeutic strategy of targeting host factors
that modulate intracellular M. tuberculosis infection and replication.
Repurposing of agents already in clinical use for other indications
could expedite the testing of this strategy for tuberculosis.
The general idea of modulating the host response to improve
the outcome of tuberculosis treatment has circulated for some
time. This concept however, is enormously complex as any benefit
to the patient must integrate the impact of host-targeted inter-
vention across all cell and tissue types and all systemic responses,
and throughout the whole course of infection. Thus, benefits on a
cellular, macrophage level may be counterbalanced by detrimental
systemic effects involving numerous cell types and cytokine
responses, or vice versa. Further, interventions with benefits at
one point in infection, for example early in an inflammatory
process, may not necessary be beneficial late in infection.
Nevertheless, treatments that limit inflammation have been used
both clinically and in experimental settings as adjunctive therapy
for conventional antibiotics. Treatment of human patients with
corticosteroids results in a modest decrease in mortality and is
helpful in some forms of extrapulmonary tuberculosis including
meningitis and pleural disease [56], possibly by limiting host
inflammatory related tissue damage and/or by allowing
M. tuberculosis to transition into a state of active replication in
which it is sensitive to antibiotics [57]. Similarly, while anti-TNF-a
agents lead to reactivation of mycobacterial disease, at the same
time, blocking TNF-a has been suggested to favor a host
microenvironment that favors bacterial clearance, particularly in
the face of tubercular chemotherapy. Specifically, agents that
either directly block TNF-a or inhibit signaling mechanisms that
indirectly result in TNF-a production have been used to enhance
the responsiveness of bacteria to conventional antibiotics. The
TNF-a blocking agent etanercept increased the efficacy of
conventional antibiotics during the chronic phase of infection,
when the bulk of the bacterial are thought to be replicating slowly
[58]. FDA-approved phosphodiesterase (PDE) inhibitors, which
alter intracellular levels of cAMP resulting in reduced TNF-a
secretion, likewise have been shown to reduce bacterial burden in
rabbit and mouse models of infection when combined with current
antimycobacterial antibiotics [42,59]. Of note, an inhibitor of
PDE-4 enhanced the effect of isoniazid on clearance of bacteria,
but did not have an effect alone [42]. Inhibitors of PDE-3 and
PDE-5 were not tested in the absence of standard tuberculosis
therapy, so whether they would have an effect alone is unknown
[59].
In contrast to work studying therapies that potentially manip-
ulate immunity at a systemic level, a growing body of literature
including this current work supports the idea that targeting specific
host-pathways to enhance molecular mechanisms for bacterial
clearance on the cellular level may be an effective adjunctive
strategy for treatment [60]. Based on known host-pathogen biology
or the RNAi screens described above, a variety of host targets have
been identified and tested in animal models. Targeting lipid
metabolism,a liverX receptorinhibitorreduced bacterialburdenin
the lungs of mice infected with M. tuberculosis [61]. As noted above,
imatinib, an ABL inhibitor, has been shown to reduce bacterial
burden in a murine model of infection [28]. Additionally, a TGF-b
receptor inhibitor [11] and a GPR109A inhibitor [46], selected for
study based on findings from the RNAi screen of M. tuberculosis
infected THP-1 cells, were both shown to be similarly effective in
reducing the burden of disease in mice. As the models for infection
and treatment differ from study to study, it is difficult to directly
compare efficacy between studies. Unlike the PDE inhibitors
however, the liver X receptor inhibitor, ABL inhibitor, TGF-beta
inhibitor, GPR109A inhibitor, and now an EGFR inhibitor all have
efficacy even in absence of traditional tuberculosis therapy. These
results suggest that enhancing host mechanisms of intracellular
killing is a viable option for novel TB therapies, while reiterating the
need tomove quicklyfrominvitrocellularmodelstoinfected animals
to determine the effect of an intervention on the complex, intact
immune response of a whole organism. Additionally, efforts to
determinethetimingduringaninfectiousprocessorthehost genetic
background where host intervention might be most beneficial will
be important to such approaches.
As the problems of MDR- and XDR-TB grow globally,
identifying new therapeutic approaches will be critical for
decreasing morbidity and mortality, and potentially disrupting
the transmission of these highly resistant strains. Traditional drug
development pipelines for anti-tuberculosis antibiotics have proven
slow to move from lead compounds to clinically deployed medica-
tions. As several host-acting compounds that are already in clinical
use with well-understood pharmacology and side effects have been
shown to be effective in animal models of disease, such compounds
could be rapidly tested in expanded animal models of infection
and perhaps even moved to humans directly, given the limitations
of existing animal models, to clarify the role of host-targeted
therapies on treatment efficacy and duration. Alternatively, for
some host-modulating compounds that are commonly used within
patient populations (i.e, calcium channel blockers, NSAIDs,
SSRIs), retrospective data may exist to provide initial support
for any potential benefit of these host-targeted inhibitors. While
some host-targeted therapies, including some kinase inhibitors,
would currently be relatively expensive to administer, they are
within the cost range of other medications being studied for use
against for highly drug-resistant tuberculosis, including linezolid,
and with time, their costs will drop as they become available off
patent [62]. Others, such as some SSRIs or calcium-channel
blockers, are currently inexpensive and would be amenable to
inclusion in treatment regimens. Given the current state of
tuberculosis, with rising incidence of MDR, XDR, and even
TDR-TB, novel strategies are required that move beyond the
conventional paradigm of an antibiotic that kills the bacterium in
axenic culture. Targeting the host is one such strategy that can be
tested as a feasible path forward exists, facilitated by the
repurposing of current drugs.
Materials and Methods
Ethics statement
Animal work was approved by Massachusetts General Hospital
IACUC (protocol number 2009N000203) or the Harvard Medical
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03000). All protocols conform to the USDA Animal Welfare Act,
institutional policies on the care and humane treatment of animals,
the ‘‘ILAR Guide for the Care and Use of Laboratory Animals,’’
and other applicable laws and regulations.
Imaging assay protocol
J774 macrophages were seeded into 96-well black clear-bottom
plates. M. tuberculosis strain H37Rv constitutively expressing GFP
[18] was grown to mid-log phase in axenic culture, washed in PBS,
briefly opsonized in heat-inactivated horse serum, and used to
infect cells at an MOI of 1:1. Infection was allowed to progress for
four hours, then media was aspirated, cells were washed once with
PBS, and media containing the screening compounds at an
average concentration of 5 uM was added back to cells. Three
days after infection, media was aspirated, cells were washed once
with PBS, and fixed with 4% paraformaldehyde with Triton X-
100 and DAPI.
Image acquisition and analysis
Plates were imaged using an Image Xpress Micro high-
throughput microscope (Molecular Devices). Images were taken
witha 46objective at four sites perwell. Imageswerethen analyzed
using CellProfiler open-source software [19]. The imaging-analysis
pipeline is openly available (http://cellprofiler.org/published_
pipelines.shtml) and included correction to homogenize illumina-
tion over each field, a filter to remove any large debris from the
analysis, identification and quantitation of DAPI-stained nuclei,
identification, quantitation, and pixel intensity calculation for GFP-
expressing bacteria. The final output was calculated as (average
GFP pixel intensity per bacterium across the field)6(number of
bacteria identified in the field)/number of nuclei per field. The four
images sites per well were averaged. To identify hits we used p-
values obtained by bootstrap Monte Carlo and composite z-scores
(see Methods S1).
J774 infections for CFU
J774 cells were seeded into 24 well plates. M. tuberculosis strain
H37Rv was prepared as described above, then used to infect cells
at an MOI of 1:1. Phagocytosis was allowed to progress for
4 hours; cells were then washed once with PBS and fresh media
containing compound was added back. Day 3 after infection, cells
were washed once with PBS, lysed in 0.5% Triton X-100, and
plated on 7H10 plates in serial dilutions.
BMDM isolation and infections
Bone marrow was obtained from C57BL/6 mice. In brief, adult
male mice were euthanized and femurs and tibias were harvested.
Bone marrow was flushed from the cells, resuspended in DMEM,
and plated non-tissue culture treated dishes in DMEM media
containing 2 mM L-glutamine, 20% fetal bovine serum, and
25 ng/ml recombinant mouse M-CSF. Cells were harvested day 6
after bone marrow isolation and either plated for subsequent
infection or frozen. For infections, cells were plated in 24 well
plates and infected as above with H37Rv. Media was changed
every two days. Day 5 after infection, cells were washed once with
PBS, lysed with 0.5% Triton X-100, and plated for CFU.
siRNA and blocking antibodies
For siRNA silencing experiments, J774 cells were plated in a
6-well dish. 20 pmol siRNA duplex was added in Optimem
(Gibco) with 9 ml Lipofectamine RNAiMax (Invitrogen) at 24 h
and again at 48 h after plating. The following day, cells were
harvested, counted and re-plated for M. tuberculosis infections. 24 h
after replating, the cells were infected with H37Rv as described
above. To assess the efficiency of silencing, lysates were prepared
at the same timepoint that the cells are infected with M. tuberculosis.
For experiments blocking EGFR signaling, anti-EGFR antibody
225 (Millipore) and EGFR antibody Ab-5 (Thermo Scientific)
were used at a final concentration of 20 nM. Media containing
antibodies was replenished every 24 h.
Macrophage assays
For monitoring LC3 conversion by Western blot analysis,
2610
5 J774 macrophages were plated per well in 12 well dishes
and were infected with H37Rv at an MOI=1. After 4 h the
infected monolayer was washed once with PBS and media
containing inhibitors was added. Three hours later the cells were
washed, and protein lysates were prepared and run on a 15%
SDS-PAGE gel. LC3-I and LC3-II were detected using an
antibody from Cell Signaling Technologies. For TNF-a ELISAs,
J774 or mouse BM macrophages were plated at 5610
4 cells per
well in a 96 well plate and infected at an MOI=1. Monolayers
were washed with PBS after 4 h phagocytosis and media with
inhibitors was added. Cell supernatants were collected 24 h later,
and assayed for TNF-a using an ELISA kit (Invitrogen). For
phospho-p38 and p38 westerns, J774 cells were infected with
H37Rv at an MOI of 1. Phagocytosis was allowed to proceed for
4 hours. Cells were then washed with warmed media, and then
treated with gefitinib or DMSO carrier. Cells were harvested at
0 minutes, 15 minutes, 30 minutes, and 60 minutes after drug
treatment and probed for phospho-p38 or p38 using antibodies
from Cell Signaling Technologies.
Mouse infections
BALB/c mice were infected in a Madison aerosol chamber as
previously described [63]. 5 mice were sacrificed day 1 after
infection, and their lungs were homogenized and plated for CFU
to determine the number of implanted bacteria. Infection in the
remaining mice was allowed to progress for 7 days. Beginning day
8 after infection, mice were then given intraperitoneal injections of
gefitinib at 100 mg/kg or DMSO carrier for 6 days. Day 14 after
infection, 5 mice in each experimental group were sacrificed, and
lungs were homogenized and plated for CFU.
Supporting Information
Figure S1 Positive controls for development of high-
content imaging assay. J774 cells in 96-well dishes were
infected with GFP-expressing H37Rv at an MOI of 1:1. Cells were
then treated with rifampin at the indicated concentrations. Day 3
after infection, cells were fixed, stained with DAPI, and imaged.
(A) Nuclei of macrophages are in blue; GFP-expressing M.
tuberculosis are in green. (B) GFP channel only. For each image set
image contrast was adjusted equally for every image to promote
print quality. Images were not adjusted prior to analysis.
(PDF)
Figure S2 Percent representation of compound catego-
ries in input library.
(PDF)
Figure S3 Fluoxetine re-testing in J774 macrophages
using the image analysis assay. J774 cells were seeded into
96-well plates at ,3000 cells/well and allowed to adhere
overnight. They were then infected with H37Rv-GFP at an
MOI of 1:1. After 4 hours of phagocytosis, cells were washed, and
fluoxetine at the indicated concentrations or DMSO control was
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with DAPI. The imaging pipeline described in detail in Methods
S1 was used to measure normalized integrated GFP intensity (A)
and quantify DAPI-stained nuclei compared to DMSO control for
each condition (B).
(PDF)
Figure S4 Gefitinib re-testing in J774 macrophages
using the image analysis assay. J774 cells were seeded into
96-well plates at ,3000 cells/well and allowed to adhere
overnight. They were then infected with H37Rv-GFP at an
MOI of 1:1. After 4 hours of phagocytosis, cells were washed, and
gefitinib at the indicated concentrations or DMSO control was
added to wells. Day 3 after infection, cells were fixed and stained
with DAPI. The imaging pipeline described in detail in Methods
S1 was used to measure normalized integrated GFP intensity (A)
and quantify DAPI-stained nuclei compared to DMSO control for
each condition (B).
(PDF)
Figure S5 GNF2 re-testing in J774 macrophages using
the image analysis assay. J774 cells were seeded into 96-well
plates at ,3000 cells/well and allowed to adhere overnight. They
were then infected with H37Rv-GFP at an MOI of 1:1. After
4 hours of phagocytosis, cells were washed, and GNF2 at the
indicated concentrations or DMSO control was added to wells.
Day 3 after infection, cells were fixed and stained with DAPI. The
imaging pipeline described in detail in Methods S1 was used to
measure normalized integrated GFP intensity (A) and quantify
DAPI-stained nuclei compared to DMSO control for each
condition (B).
(PDF)
Figure S6 AKTi1/2 re-testing in J774 macrophages
using the image analysis assay. J774 cells were seeded into
96-well plates at ,3000 cells/well and allowed to adhere
overnight. They were then infected with H37Rv-GFP at an
MOI of 1:1. After 4 hours of phagocytosis, cells were washed, and
AKTi1/2 at the indicated concentrations or DMSO control was
added to wells. Day 3 after infection, cells were fixed and stained
with DAPI. The imaging pipeline described in detail in Methods
S1 was used to measure normalized integrated GFP intensity (A)
and quantify DAPI-stained nuclei compared to DMSO control for
each condition (B).
(PDF)
Figure S7 FTT re-testing in J774 macrophages using the
image analysis assay. J774 cells were seeded into 96-well
plates at ,3000 cells/well and allowed to adhere overnight. They
were then infected with H37Rv-GFP at an MOI of 1:1. After
4 hours of phagocytosis, cells were washed, and FTT at the
indicated concentrations or DMSO control was added to wells.
Day 3 after infection, cells were fixed and stained with DAPI. The
imaging pipeline described in detail in Methods S1 was used to
measure normalized integrated GFP intensity (A) and quantify
DAPI-stained nuclei compared to DMSO control for each
condition (B).
(PDF)
Figure S8 Ritanserin re-testing in J774 macrophages
using the image analysis assay. J774 cells were seeded into
96-well plates at ,3000 cells/well and allowed to adhere
overnight. They were then infected with H37Rv-GFP at an
MOI of 1:1. After 4 hours of phagocytosis, cells were washed, and
ritanserin at the indicated concentrations or DMSO control was
added to wells. Day 3 after infection, cells were fixed and stained
with DAPI. The imaging pipeline described in detail in Methods
S1 was used to measure normalized integrated GFP intensity (A)
and quantify DAPI-stained nuclei compared to DMSO control for
each condition (B).
(PDF)
Figure S9 Testing selected hits for activity against M.
tuberculosis growing in axenic culture. M. tuberculosis was
grown to mid-log phase, then diluted back to an OD600 of 0.05.
Compounds were added at the concentrations indicated, and the
cultures were incubated at 37uC. On days 3, 7, and 14 after
inoculation, cells were mixed, and OD600 was recorded. At the
tested concentrations, which are the maximum concentrations
used in macrophages, no compounds had significant activity
against M. tuberculosis in axenic culture.
(PDF)
Figure S10 Targeting protein expression in J774 mac-
rophages using siRNA. J774 macrophages were transfected
with a pool of 5 siRNAs targeting AKT1, AKT2, AKT3, or ABL1
on two consecutive days. Control samples were transfected with a
pool of 5 nonspecific siRNAs. 24 h after the second transfection
the cells were harvested and split into fresh plates for 24 h at which
time lysates were prepared for (A) Western blot analysis. To assess
protein levels present in the cells at the time of infection, lysates
were prepared at the same time-point after transfection that the
cells are infected with M. tuberculosis. Samples were blotted with
antibodies specific for AKT1, AKT2, AKT3 or ABL1. Blots were
stripped and reprobed with a–actin for loading control. (B) To
assess efficiency of phagocytosis the cells were infected with wild-
type H37Rv cells for a period of 4 h at which time the infected
monolayers were washed, lysed, and CFU were enumerated by
plating on agar plates.
(PDF)
Figure S11 Detection of EGFR transcript by PCR in J774
cells. RNA was isolated from J774 cells. 1 mg of RNA was used as
template for cDNA production with (+RT) or without (2RT)
addition of reverse transcriptase. The cDNA was used as a
template for standard PCR using primers to amplify a small
fragment of cDNA crossing a splice junction. A band correspond-
ing to transcript was detected in the +RT but not 2RT samples
after 25 cycles. Shown are the samples after 35 cycles. For
comparison, 20 ml of 50 bp ladder (NEB) were run in lane 1. See
Methods S1 for full protocol details including primer sequences.
(PDF)
Figure S12 CellProfiler identification of bacteria and
nuclei. A. Illumination-corrected DAPI image (nuclei). B.
CellProfiler identification of nuclei (green outlines: nuclei, red
outlines: excluded shapes based on size criteria). C. Illumination-
corrected GFP image (bacteria). D. CellProfiler identification of
bacteria (green outlines: bacteria).
(PDF)
Methods S1 Additional methods including statistics,
details of assay development, CellProfiler analysis and
EGFR PCR.
(DOCX)
Table S1 Compounds included in screened library and
complete hit list with composite Z-scores and Monte
Carlo bootstrap-determined p-values.
(XLSX)
Acknowledgments
We thank L. Verplank, N. Tolliday, T. Hasaka, M. Palmer, and the Broad
Institute Chemical Biology platform for technical assistance, data
Host-Targeted Small Molecules to Inhibit Mtb
PLOS Pathogens | www.plospathogens.org 14 February 2014 | Volume 10 | Issue 2 | e1003946management, and advice on assay development; S. Singh for critical
manuscript review and assistance with revision; A. Stern for helpful
discussion and advice throughout the project; N. Gray for novel kinase
inhibitors; J. Cox for the luciferase-expressing strain of M. tuberculosis
Erdman.
Author Contributions
Conceived and designed the experiments: SAS AKB NS EJR DTH.
Performed the experiments: SAS AKB MRS SSL KS NS. Analyzed the
data: SAS AKB MRS SSL KS MV MAB AEC CBM DTH. Contributed
reagents/materials/analysis tools: CBM. Wrote the paper: SAS AKB
DTH.
References
1. Deretic V, Singh S, Master S, Harris J, Roberts E, et al. (2006) Mycobacterium
tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host
defence mechanism. Cellular Microbiology 8: 719–727.
2. Malik ZA, Iyer SS, Kusner DJ (2001) Mycobacterium tuberculosis Phagosomes
Exhibit Altered Calmodulin-Dependent Signal Transduction: Contribution to
Inhibition of Phagosome-Lysosome Fusion and Intracellular Survival in Human
Macrophages. The Journal of Immunology 166: 3392–3401.
3. Jayachandran R, Sundaramurthy V, Combaluzier B, Mueller P, Korf H, et al.
(2007) Survival of Mycobacteria in Macrophages Is Mediated by Coronin
1-Dependent Activation of Calcineurin. Cell 130: 37–50.
4. Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM (2010)
Eicosanoid pathways regulate adaptive immunity to Mycobacterium tubercu-
losis. Nat Immunol 11: 751–758.
5. Chen M, Divangahi M, Gan H, Shin DSJ, Hong S, et al. (2008) Lipid mediators
in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in
the induction of macrophage death. The Journal of Experimental Medicine 205:
2791–2801.
6. Martin CJ, Booty MG, Rosebrock TR, Nunes-Alves C, Desjardins DM, et al.
(2012) Efferocytosis Is an Innate Antibacterial Mechanism. Cell Host & Microbe
12: 289–300.
7. Shin D-M, Jeon B-Y, Lee H-M, Jin HS, Yuk J-M, et al. (2010) Mycobacterium
tuberculosis Eis Regulates Autophagy, Inflammation, and Cell Death through
Redox-dependent Signaling. PLoS Pathog 6: e1001230.
8. Master SS, Rampini SK, Davis AS, Keller C, Ehlers S, et al. (2008)
Mycobacterium tuberculosis Prevents Inflammasome Activation. Cell Host &
Microbe 3: 224–232.
9. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, et al. (2008) Foamy
macrophages from tuberculous patients’ granulomas constitute a nutrient-rich
reservoir for M. tuberculosis persistence. PLoS Pathogens 4: e1000204.
10. Kumar D, Nath L, Kamal MA, Varshney A, Jain A, et al. (2010) Genome-wide
Analysis of the Host Intracellular Network that Regulates Survival of
Mycobacterium tuberculosis. Cell 140: 731–743.
11. Jayaswal S, Kamal MA, Dua R, Gupta S, Majumdar T, et al. (2010)
Identification of Host-Dependent Survival Factors for Intracellular Mycobacterium
tuberculosis through an siRNA Screen. PLoS Pathog 6: e1000839.
12. Kuijl C, Savage NDL, Marsman M, Tuin AW, Janssen L, et al. (2007)
Intracellular bacterial growth is controlled by a kinase network around PKB/
AKT1. Nature 450: 725–U710.
13. Tailleux L, Waddell SJ, Pelizzola M, Mortellaro A, Withers M, et al. (2008)
Probing Host Pathogen Cross-Talk by Transcriptional Profiling of Both
Mycobacterium tuberculosis and Infected Human Dendritic Cells and Macrophages.
PLoS ONE 3: e1403.
14. Stanley SA, Hung DT (2009) Chemical Tools for Dissecting Bacterial Physiology
and Virulence. Biochemistry 48: 8776–8786.
15. Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M,
et al. (2009) High Content Screening Identifies Decaprenyl-Phosphoribose 29
Epimerase as a Target for Intracellular Antimycobacterial Inhibitors. PLoS
Pathog 5: e1000645.
16. Pethe K, Bifani P, Jang J, Kang S, Park S, et al. (2013) Discovery of Q203, a
potent clinical candidate for the treatment of tuberculosis. Nat Med advance
online publication.
17. Sundaramurthy V, Barsacchi R, Samusik N, Marsico G, Gilleron J, et al. (2013)
Integration of Chemical and RNAi Multiparametric Profiles Identifies Triggers
of Intracellular Mycobacterial Killing. Cell Host & Microbe 13: 129–142.
18. Stanley SA, Grant SS, Kawate T, Iwase N, Shimizu M, et al. (2012)
Identification of Novel Inhibitors of M. tuberculosis Growth Using Whole Cell
Based High-Throughput Screening. ACS Chemical Biology 7: 1377–1384.
19. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, et al. (2006)
CellProfiler: image analysis software for identifying and quantifying cell
phenotypes. Genome Biology 7.
20. Wei X, Gao L, Zhang X, Qian H, Rowan K, et al. (2013) Introducing Bayesian
Thinking to High-Throughput Screening for False-Negative Rate Estimation.
Journal of Biomolecular Screening.
21. Ilouga PE, Hesterkamp T (2012) On the Prediction of Statistical Parameters in
High-Throughput Screening Using Resampling Techniques. Journal of
Biomolecular Screening 17: 705–712.
22. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. (2001)
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor-alpha
ı `Neutralizing Agent. New England Journal of Medicine 345: 1098–1104.
23. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, et al. (2003)
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action
and clinical management. The Lancet Infectious Diseases 3: 148–155.
24. Glosli H, Stray-Pedersen A, Brun AC, Holtmon LW, Tonjum T, et al. (2008)
Infections Due to Various Atypical Mycobacteria in a Norwegian Multiplex
Family with Dominant Interferon-gamma Receptor Deficiency. Clinical
Infectious Diseases 46: e23–e27.
25. Bekker L-G, Freeman S, Murray PJ, Ryffel B, Kaplan G (2001) TNF-alpha
Controls Intracellular Mycobacterial Growth by Both Inducible Nitric Oxide
Synthase-Dependent and Inducible Nitric Oxide Synthase-Independent Path-
ways. The Journal of Immunology 166: 6728–6734.
26. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P (2011)
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are
attenuated by antiinflammatory drugs in mice and humans. Proceedings of the
National Academy of Sciences 108: 9262–9267.
27. Harris J, Keane J (2010) How tumour necrosis factor blockers interfere with
tuberculosis immunity. Clinical & Experimental Immunology 161: 1–9.
28. Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, et al. (2011)
Imatinib-Sensitive Tyrosine Kinases Regulate Mycobacterial Pathogenesis and
Represent Therapeutic Targets against Tuberculosis. Cell Host & Microbe 10:
475–485.
29. Bruns H, Stegelmann F, Fabri M, D!hhner K, van Zandbergen G, et al. (2012)
Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for
Killing of Mycobacterium tuberculosis in Human Macrophages. The Journal of
Immunology 189: 4069–4078.
30. Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, et al. (2005)
Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2
dual inhibitors. Bioorganic & Medicinal Chemistry Letters 15: 905–909.
31. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, et al. (2005)
Identification and characterization of pleckstrin-homology-domain-dependent
and isoenzyme-specific Akt inhibitors. Biochem J 385: 399–408.
32. Alessi DRA, M.; Caudwell, B.; Cron, P.; Morrice, N.; Cohen, P.; Hemmings,
B.A. (1996) Mechanism of activation of protein kinase B by insulin and IGF-1.
EMBO J 15: 6541–6551.
33. Wong S, Witte ON (2004) The BCR-ABL Story: Bench to Bedside and Back.
Annual Review of Immunology 22: 247–306.
34. Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, et al. (2004) Sole
BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder
cell populations. Proceedings of the National Academy of Sciences of the United
States of America 101: 17456–17461.
35. Eierhoff T, Hrincius ER, Rescher U, Ludwig S, Ehrhardt C (2010) The
Epidermal Growth Factor Receptor (EGFR) Promotes Uptake of Influenza A
Viruses (IAV) into Host Cells. PLoS Pathog 6: e1001099.
36. Liu K, Gualano RC, Hibbs ML, Anderson GP, Bozinovski S (2008) Epidermal
Growth Factor Receptor Signaling to Erk1/2 and STATs Control the Intensity
of the Epithelial Inflammatory Responses to Rhinovirus Infection. Journal of
Biological Chemistry 283: 9977–9985.
37. Yan F, Cao H, Chaturvedi R, Krishna U, Hobbs SS, et al. (2009) Epidermal
Growth Factor Receptor Activation Protects Gastric Epithelial Cells From
Helicobacter pylori-Induced Apoptosis. Gastroenterology 136: 1297–
1307.e1293.
38. Lynch T (2003) Clinical benefit in NSCLC: the evidence for gefitinib (Iressa,
ZD1839). European Journal of Cancer Supplements 1: 17–22.
39. Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, et al. (2010)
Combination antibody treatment down-regulates epidermal growth factor
receptor by inhibiting endosomal recycling. Proceedings of the National
Academy of Sciences 107: 13252–13257.
40. Lee MRD, C (2005) MAP kinase p38 inhibitors: Clinical results and an intimate
look at their interactions with p38 alpha protein. Current Medicinal Chemistry
12: 2979–2994.
41. Webber JL, Tooze SA (2010) Coordinated regulation of autophagy by p38-alpha
MAPK through mAtg9 and p38IP. EMBO J 29: 27–40.
42. Subbian S, Tsenova L, O’Brien P, Yang G, Koo M-S, et al. (2011)
Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isonia-
zid-Mediated Clearance of Mycobacterium tuberculosis in Rabbit Lungs. PLoS
Pathog 7: e1002262.
43. Gupta S, Salam N, Srivastava V, Singla R, Behera D, et al. (2009) Voltage
Gated Calcium Channels Negatively Regulate Protective Immunity to
Mycobacterium tuberculosis. PLoS ONE 4: e5305.
44. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, et al. (2011)
Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-
Induced Efflux Mechanism. Cell 145: 39–53.
45. Gupta ST, Sandeep; Almeida, Deepak V.; Maiga, Mariama C.; Ammerman,
Nicole C.; Bishai, William R. (2013) Acceleration of tuberculosis treatment by
adjunctive therapy with verapamil as an efflux inhibitor. AJRCCM 10.1164/
rccm.201304-0650OC.
Host-Targeted Small Molecules to Inhibit Mtb
PLOS Pathogens | www.plospathogens.org 15 February 2014 | Volume 10 | Issue 2 | e100394646. Singh V, Jamwal S, Jain R, Verma P, Gokhale R, et al. (2012) Mycobacterium
tuberculosis-Driven Targeted Recalibration of Macrophage Lipid Homeostasis
Promotes the Foamy Phenotype. Cell Host & Microbe 12: 669–681.
47. de las Casas-Engel M, Dominguez-Soto A, Sierra-Filardi E, Bragado R, Nieto
C, et al. (2013) Serotonin Skews Human Macrophage Polarization through
HTR2B and HTR7. The Journal of Immunology 190: 2301–2310.
48. Gaskill PC, Loreto; Eugenin, Eliseo A; Berman, Joan W (2012) Characterization
and function of the human macrophage dopaminergic system: implications for
CNS disease and drug abuse. Journal of Neuroimflammation 9: 203–216.
49. Izeboud CM, JAJ; Monshouwer, M; van Miert, ASJPAM; Witkamp, RF (1999)
Participation of beta-Adrenergic Receptors on Marophages in Modulation of
LPS-Induced Cytokine Release. Journal of Receptors and Signal Transduction
19: 191–202.
50. SternbergEM, TrialJ, Parker CW (1986) Effect of serotonin onmurine macrophages:
suppression of Ia expression by serotonin and its reversal by
5-HT2 serotonergic receptor antagonists. The Journal of Immunology 137: 276–282.
51. Cloez-Tayarani I, Petit-Bertron A-F, Venters HD, Cavaillon J-M (2003)
Differential effect of serotonin on cytokine production in lipopolysaccharide-
stimulated human peripheral blood mononuclear cells: involvement of
5-hydroxytryptamine2A receptors. International Immunology 15: 233–240.
52. Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, et al. (2012) Host
Genotype-Specific Therapies Can Optimize the Inflammatory Response to
Mycobacterial Infections. Cell 148: 434–446.
53. Roca FJ, Ramakrishnan L (2013) TNF Dually Mediates Resistance and
Susceptibility to Mycobacteria via Mitochondrial Reactive Oxygen Species. Cell
153: 521–534.
54. Koo M-S, Manca C, Yang G, O’Brien P, Sung N, et al. (2011) Phosphodiesterase
4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of
Mycobacterium tuberculosis in the Lungs of Infected Mice. PLoS ONE 6: e17091.
55. Shubin H, Lambert RE, Heiken CA, Sokmensuer A, Glaskin A (1959) Steroid
therapy and tuberculosis. Journal of the American Medical Association 170:
1885–1890.
56. Critchley JA, Young F, Orton L, Garner P (2013) Corticosteroids for prevention
of mortality in people with tuberculosis: a systematic review and meta-analysis.
The Lancet Infectious Diseases 13: 223–237.
57. Wallis RS (2005) Reconsidering Adjuvant Immunotherapy for Tuberculosis.
Clinical Infectious Diseases 41: 201–208.
58. Skerry C, Harper J, Klunk M, Bishai WR, Jain SK (2012) Adjunctive TNF
Inhibition with Standard Treatment Enhances Bacterial Clearance in a Murine
Model of Necrotic TB Granulomas. PLoS ONE 7: e39680.
59. Maiga M, Agarwal N, Ammerman NC, Gupta R, Guo H, et al. (2012)
Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed
Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse
Model. PLoS ONE 7: e30749.
60. Schwegmann A, Brombacher F (2008) Host-Directed Drug Targeting of Factors
Hijacked by Pathogens. Science Signaling 1: re8.
61. Korf H, Vander Beken S, Romano M, Steffensen KR, Stijlemans B, et al. (2009)
Liver X receptors contribute to the protective immune response against
Mycobacterium tuberculosis in mice. The Journal of Clinical Investigation 119:
1626–1637.
62. Lee M, Lee J, Carroll MW, Choi H, Min S, et al. (2012) Linezolid for Treatment
of Chronic Extensively Drug-Resistant Tuberculosis. New England Journal of
Medicine 367: 1508–1518.
63. Stanley SA, Kawate T, Iwase N, Shimizu M, Clatworthy AE, et al. (2013)
Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium
tuberculosis by targeting FadD32. Proceedings of the National Academy of
Sciences 110: 11565–11570.
Host-Targeted Small Molecules to Inhibit Mtb
PLOS Pathogens | www.plospathogens.org 16 February 2014 | Volume 10 | Issue 2 | e1003946